Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ago Ahene"'
Autor:
Hong Xiang, Abigael G. Chan, Ago Ahene, David I. Bellovin, Rong Deng, Amy W. Hsu, Ursula Jeffry, Servando Palencia, Janine Powers, James Zanghi, Helen Collins
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibit
Externí odkaz:
https://doaj.org/article/631148f01f704dc69b35977cd33a11de
Autor:
Yero Espinoza, David Wong, Ago Ahene, Kenneth Der, Zachary Martinez, John Pham, Ronald R. Cobb, Shauna Farr-Jones, James. D. Marks, Milan T. Tomic
Publikováno v:
Toxins, Vol 11, Iss 6, p 345 (2019)
Botulinum neurotoxins (BoNT) are potential biothreat agents due to their high lethality, potency, and ease of distribution, thus the development of antitoxins is a high priority to the US government. This study examined pre-clinical pharmacokinetic s
Externí odkaz:
https://doaj.org/article/086a1b33951547fc8503f1a30d1a4591
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose A population pharmacokinetic (PK) analysis of the anti-fibroblast growth factor receptor 2b antibody, bemarituzumab, was performed to evaluate the impact of covariates on the PK and assess whether dose adjustment is necessary for a future pha
Autor:
Yuying Gao, Lucy Liu, Lyndah Dreiling, Helen Collins, Amy W. Hsu, Ago Ahene, Monica Macal, Hong Xiang
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To report population pharmacokinetic (PK) analysis of the phase 1 study (FPA144-001, NCT02318329) and to select a clinical dose and schedule that will achieve an empirical target trough concentration (Ctrough) for an anti-fibroblast growth fa
Autor:
Abigael G. Chan, Ago Ahene, Servando Palencia, Rong Deng, Janine Powers, James Zanghi, Amy W. Hsu, David Bellovin, Ursula Jeffry, Hong Xiang, Helen Collins
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibit
Autor:
Shauna Farr-Jones, Yero Espinoza, Ronald R. Cobb, Milan T. Tomic, John Pham, Zachary Martinez, David Wong, Ago Ahene, James D. Marks, Kenneth Der
Publikováno v:
Toxins, Vol 11, Iss 6, p 345 (2019)
Toxins
Volume 11
Issue 6
Toxins, vol 11, iss 6
Toxins
Volume 11
Issue 6
Toxins, vol 11, iss 6
Botulinum neurotoxins (BoNT) are potential biothreat agents due to their high lethality, potency, and ease of distribution, thus the development of antitoxins is a high priority to the US government. This study examined pre-clinical pharmacokinetic s
Autor:
Douglas Clark, Changhua Ji, Ying C. Ou, Xingrong Liu, Jun Zhang, Matthew W. Cooper, Ago Ahene, Su-Chun Hsieh
Publikováno v:
Pharmaceutical Research. 31:809-818
This study was to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of a chimeric protein, CD4-anchoring bi-functional fusion inhibitor (CD4-BFFI), in monkeys and assess the feasibility for HIV-1 treatment in humans.The serum concentra
Publikováno v:
Molecular Endocrinology. 18:874-887
The vitamin D analog, 1alpha-fluoro-16-ene-20-epi-23-ene-26,27-bishomo-25-hydroxyvitamin D(3) (Ro-26-9228) is tissue selective, with a gene regulation preference for bone over duodenum in vivo. In the human osteoblast-like cells, hFOB, the vitamin D
Publikováno v:
Endocrinology. 143:1625-1636
We have examined several analogs of 1α,25-dihydroxyvitamin D3 [1,25-(OH)2D3] in an animal model of osteoporosis (ovariectomized rats) to identify a compound with a greater therapeutic range than 1,25-(OH)2D3 for treatment of this bone disease. Here,